LUPUS FOUNDATION OF AMERICA, INC.
CORRECTIVE ACTION PLAN
For the Year Ended September 30, 2024
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Lupus Foundation of America, Inc. (the Foundation) submits the following corrective action plan for the year ended September 30, 2024.
Independent Public Ac...
LUPUS FOUNDATION OF AMERICA, INC.
CORRECTIVE ACTION PLAN
For the Year Ended September 30, 2024
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Lupus Foundation of America, Inc. (the Foundation) submits the following corrective action plan for the year ended September 30, 2024.
Independent Public Accounting Firm:
CBIZ CPAs P.C.
1899 L Street NW, Suite 850
Washington, DC 20036
Audit Period: The finding from the September 30, 2024 schedule of findings and questioned costs is discussed below. The finding is numbered consistently with the number assigned in the schedule.
FEDERAL AWARD FINDINGS AND QUESTIONED COSTS
Finding No. 2024-001: Special Tests and Provisions – Significant Deficiency – Internal Control and Compliance Finding
ALN 93.068 – Chronic Diseases: Research, Control, and Prevention, Grant Number 5NU58DP006907-04-00, Grant Period: September 30, 2020 to September 29, 2025
Condition
The Foundation did not have adequate internal control procedures in place to ensure that certain disclaimers required by the grant agreements are included in written conference materials or publications.
Context
One of two conference materials we reviewed did not include the required disclaimer.
Recommendation
It was recommended that management enhance current internal control procedures to ensure that the Foundation is in compliance with the grant’s special provisions that requires certain disclaimers in written conference materials or publications.
Action Taken
PULSE Team Check-Ins:
• Incorporate disclaimer compliance as a standing agenda item during bi-weekly PULSE team meetings to review upcoming materials and confirm adherence to requirements.
• The Directors (Content and Federal Grants and Public Health Programs) Program Manager will be assigned to monitor and track the inclusion of disclaimers.
Quarterly Compliance Review:
• Implement a quarterly review process to assess all conference materials and publications for the inclusion of required disclaimers.
• Document review findings and corrective actions, if applicable, to ensure consistent compliance.
Executive Leadership Reporting:
• Provide updates to executive leadership on all conference materials and publications produced and disclaimer compliance status, including any identified issues and corrective actions taken.
• Share compliance trends and recommendations for ongoing improvement to reinforce accountability and oversight.
Contact Person
Responsible for
Corrective Action: Dr. Melicent R. Miller, Director, Federal Grants and Public Health Programs
If the US Department of Health and Human Services has questions regarding this plan, please call Cynthia R. Meekins, Chief Financial Officer at 202.349.1141 or meekins@lupus.org
Sincerely,
Cynthia R. Meekins, MBA
Chief Financial Officer
Lupus Foundation of America